ABSTRACT
At present, there are no evidence-based guidelines regarding the treatment of patients with disorders of consciousness (DOC). 1 Nevertheless, some studies have recently aimed to demonstrate the potential therapeutic effect of different pharmacologic or nonpharmacologic interventions: a recent controlled clinical trial showed a beneficial effect of amantadine in posttraumatic patients with DOC 2 and a controlled case study has assessed the role of thalamic deep brain stimulation in patients in a minimally conscious state (MCS) following a brain trauma. 3 In terms of noninvasive intervention, transcranial direct current stimulation (tDCS) has been previously reported to transiently improve working memory and attention by stimulating the left dorsolateral prefrontal (DLPF) cortex in healthy subjects 4, 5 and patients with stroke, 6 Parkinson disease, 7 or Alzheimer disease. 8 Previous studies in healthy subjects reported no major adverse effects of tDCS: most often encountered were the sensation of tingling (76%), itching (68%), slight burning (54%), or mild pain (25%).
We aimed to assess the effect of a single session of anodal tDCS of the left DLPF cortex on consciousness, as evaluated by means of the Coma Recovery Scale-Revised (CRS-R), in patients in a vegetative state/unresponsive wakefulness syndrome (VS/UWS; i.e., only showing reflex movements) 10, 11 and in MCS (showing reproducible but inconsistent signs of consciousness) in a double-blind randomized sham-controlled crossover study.
METHODS Outcomes. The primary research question was whether anodal tDCS, as compared to sham stimulation, would improve consciousness (as measured by changes in CRS-R total scores) in a convenience sample of VS/UWS and MCS patients. Our second outcome was whether the tDCS had an impact on CRS-R subscales in MCS patients. Finally, followup outcome data were acquired 12 months after inclusion using the Glasgow Outcome Scale-Extended to assess the longterm effect of tDCS.
Patients. We prospectively enrolled medically stable patients in VS/UWS or MCS hospitalized in the Neurology Department of the University Hospital of Liège or in the Intercommunale de Soins Spécialisés de Liège rehabilitation center. Inclusion criteria were traumatic and nontraumatic etiology of VS/UWS or MCS according to published diagnostic criteria 12 during the acquisition period. We excluded patients in coma, 10 with less than 1 week after acute brain insult, with fluctuating diagnosis on baseline assessment, and with a metallic cerebral implant or pacemaker (in line with the safety criteria for tDCS in humans). 13 Patients were studied free of sedative drugs and Na 1 or Ca 11 channel blockers (e.g., carbamazepine) or NMDA receptor antagonists (e.g., dextromethorphan) to avoid any interaction with the presumed neuromodulatory effects of tDCS.
14 Medication (2 patients received amantadine), physiotherapy, and rehabilitation were kept unchanged throughout the experiment.
Standard protocol approvals, registrations, and patient consents. Written informed consent was obtained by the legal representative. The study was approved by the ethics committee of the University and University Hospital of Liège, Belgium (ClinicalTrials.gov NCT01673126).
Materials. tDCS is a form of noninvasive cortical stimulation, modulating cortical excitability at stimulation sites via weak polarizing currents. Each patient received both anodal and sham tDCS stimulations in randomized order. A computer-generated randomization sequence was used to assign in a 1:1 ratio the first session as anodal tDCS or sham tDCS. Randomization was stratified by study center. For the sham session, the employed tDCS device (Magstim Eldith 1 Channel DC Stimulator Plus, Magstim Company Ltd., Whitland, Wales) offers a built-in placebo mode, which is activated by an anonymous code number and includes ramp periods at the beginning and the end of sham stimulation to mimic the somatosensory artifact of real tDCS. For each patient, the experimenter received 2 codes from an independent person, one corresponding to an anodal stimulation and the other one to sham stimulation. Thus, placebo or sham tDCS could be identified by neither the blinded experimenter who administered tDCS and CRS-R nor by any of the patients.
Direct current was applied by a battery-driven constant current stimulator using saline-soaked surface sponge electrodes (7 3 5 cm) with the anode (increasing cortical excitability) positioned over the left DLPF cortex (F3 according to the 10-20 international system for EEG placement) 15 and the cathode (i.e., reference electrode) placed over the right supraorbital region, as described previously (figure 1). 16 During tDCS, the current was increased to 2 mA from the onset of stimulation and applied for 20 minutes. For the sham condition, the same electrode placement was used as in the stimulation condition, but the current was applied for 5 seconds, and was then ramped down.
Impedances were kept ,10 kV and voltage ,26 V. tDCS and sham were tested in random order in 2 separate sessions separated by 48 hours. According to the literature, the effects of a single session of anodal tDCS are expected to last for a maximum of 2 hours. 17 Hence, patients were expected to return back to their initial clinical status between the 2 sessions of stimulation (i.e., 48 hours).
tDCS treatment effect was assessed by means of standardized CRS-R assessments performed by trained and experienced blinded assessors. 18 The CRS-R consists of 23 hierarchically arranged items that comprise 6 subscales addressing auditory, visual, motor, verbal, communication, and arousal functions. Scoring is based on the presence or absence of specific behavioral responses to sensory stimuli administered in a standardized manner. The lowest item on each subscale represents reflexive activity, whereas the highest items represent cognitively mediated behaviors. A.T. enrolled the patients and assigned patients to intervention. CRS-R examinations were performed 15 directly before and after the anodal tDCS and sham tDCS sessions. For the baseline assessment, 2 blinded assessors (A.T. and M.A.B.) independently performed CRS-R assessments 18 in randomized order, permitting inter-rater comparisons. Patient outcome was assessed 12 months after the trial using the Glasgow Outcome Scale-Extended to assess the long-term effects of tDCS on clinical evolution of patients. 19 Good outcome was defined by a score .4 (i.e., return to independent living).
Data analyses. Statistical analysis was performed using Stata (Stata Statistical Software 11.2, StataCorp, College Station, TX). At the group level, we looked for a period, interaction, and treatment effect. The period effect referred to the calculation of tDCS 2 sham response differences, which were then compared according to order using a Mann-Whitney U test. The interaction effect referred to the calculation of the mean response after tDCS and sham, which was then compared according to period using a Mann-Whitney U test. If no period and interaction effect was found, then treatment effect (tDCS vs sham) was assessed using a Wilcoxon match-paired signed-rank test. Results were considered significant at p , 0.05. The clinical diagnoses for VS/UWS and MCS were considered independent and hence no correction for multiple comparisons had to be applied for the primary endpoint (i.e., assessment of change in CRS-R total score according to tDCS/sham). Multiple comparisons using Bonferroni correction (6 comparisons) had to be performed for the secondary endpoint assessment (i.e., assessment of CRS-R subscale change according to tDCS/sham) and results were considered significant at p , 0.0083 (i.e., 0.05/6).
At the individual level, tDCS responders were defined as those patients who presented a sign of consciousness (i.e., command following; visual pursuit; recognition, manipulation, localization, or functional use of objects; orientation to pain; intentional or functional communication) 18 after tDCS that was not present before anodal or before or after sham tDCS sessions.
Interrater agreement of baseline CRS-R evaluations between the 2 blinded observers was assessed using weighted kappa testing. 20 Mann-Whitney tests looked for differences in outcome between tDCS responders and nonresponders.
RESULTS We assigned 55 of the 62 eligible patients to receive both anodal and sham tDCS in a crossover study design between December 1, 2009, and June 1, 2011 (7 acute patients were excluded because they emerged from MCS between the first and second baseline assessments; see figure e-1 on the Neurology ® Web site at Neurology.org).
Patients in VS/UWS (n 5 25) had a mean age of 42 6 17 years; 9 were women; interval since insult was 24 6 48 months; 6 were posttraumatic, 9 anoxic, 9 other nontraumatic etiology (i.e., 5 cerebrovascular accident [CVA], 4 subarachnoid hemorrhage), and 1 mixed (i.e., traumatic-ischemic). Patients in MCS (n 5 30) had a mean age of 43 6 19 years; 7 were women; interval since insult was 43 6 63 months; 19 were posttraumatic, 4 anoxic, 6 nontraumatic (i.e., 3 CVA, 3 subarachnoid hemorrhage), and 1 mixed (i.e., traumatic-ischemic). Demographic data are reported in table 1. Thirty-two patients (14 in VS/UWS; mean age 46 6 17 years; 9 women; interval since insult: 44 6 72 months; 14 posttraumatic) first received anodal tDCS and 23 (11 in VS/UWS; mean age 40 6 19 years; 7 women; interval since insult: 24 6 34 months; 11 posttraumatic) first received sham stimulation (there were no significant clinical or demographic differences between the groups). Intraclass correlation coefficient was 0.90. Associated 95% confidence interval was 0.67-0.97.
At the group level, there was a treatment effect for the MCS but not for the VS/UWS patient group ( figure 2, table 2) . No period or interaction effects were observed (see tables e-1 and e-2). No effect of tDCS on any of the CRS-R subscales was observed in any group (VS/UWS or MCS).
At
showed a tDCS-related improvement (i.e., showed a clinical sign of consciousness never observed before). Two acute (,3 months) patients in VS/UWS out of 25 (8%) showed a tDCS response (i.e., showed command following and visual pursuit present after the anodal stimulation not present at baseline or pre-or post-sham tDCS). Table 3 shows the CRS-R subscale score change for tDCS responders.
No tDCS-related side effects were observed. No correlation between tDCS response and patient outcome was observed at 12 months follow-up.
DISCUSSION This double-blind sham-controlled randomized crossover study demonstrates that a single session of anodal tDCS applied to the left DLPF cortex (when employed according to published safety guidelines) 13 may transiently improve CRS-R total scores in patients in MCS without side effects. At present, there are limited evidence-based pharmacologic or nonpharmacologic treatment options for severely brain-damaged patients with DOC, especially in the chronic setting. 1 Our study illustrates the residual capacity for neural plasticity and temporary recovery of (minimal) signs of consciousness in some patients in MCS, but does not permit to make any claims regarding possible long-term tDCS effects in this setting. Future controlled clinical trials should now employ long-duration tDCS and its possible long-term effects, as has been performed for other indications such as pain 21 and depression. 22 Out of the 13 patients in MCS who showed a tDCS response, 5 were included .12 months after injury. These clinical improvements in long-standing MCS corroborate previous evidence for late recovery and neural plasticity in MCS. 23, 24 We observed no tDCS-related increase in CRS-R total scores in patients in VS/UWS, in line with previous studies showing more capacity for neural plasticity in patients in MCS. 25 It could be speculated that the observed tDCSrelated transient improvements in consciousness as assessed by changes in CRS-R total score are related to improvement in attention and working memory, 26 known to involve prefrontal cortical functioning. 27 The stimulated left DLPF area receives visual and somatosensory input from the parietal heteromodal association cortices regarding vision, motion, spatial orientation, and tactile sensations and projects to subcortical monoaminergic and cholinergic sources. 28 The DLPF is thought to play a central integrative function for motor control and behavior and is a critical component of the decision-making network. 29 The right DLPF cortex has been linked to maintenance of sustained 30 which is similarly relevant for patients with DOC. However, given the current level of evidence regarding anodal tDCS of left DLPF [4] [5] [6] [7] [8] 10 and the limited number of studies employing right anodal tDCS in normal or pathologic conditions, we opted to stimulate the former.
Previous studies have shown that anodal tDCS over the left DLPF cortex has beneficial effects on working memory in patients with Alzheimer disease 8 and Parkinson disease. 7 Similarly, there is some evidence that tDCS of the left DLPF could improve attention in stroke 31 and mild traumatic brain injury 6 patients with attention deficits. A recent fMRI study showed that tDCS of the left DLPF cortex increased functional connectivity in the "default mode" (i.e., intrinsic cortical network) and bilateral frontalparietal associative cortical networks (i.e., extrinsic networks), 16 considered to be involved in internal and external awareness, respectively. 32 Both networks are known to be dysfunctional in patients with DOC, as shown by previous PET 33 and fMRI 34 studies. A methodologic limitation of the present study and of most previous tDCS studies is the absence of MRIbased mapping of the stimulated area-especially important in our case given the presence of focal brain damage, atrophy, and injury-induced differences in brain topography. Future studies could employ patient-tailored structural MRI-guided tDCS and additionally use functional MRI to document possible tDCS-specific changes in cerebral functional connectivity in DOC. Indeed, the mechanisms of action of tDCS remain only partially understood. Direct effects of anodal tDCS include an increase of neuronal excitability via a facilitation of action potential release. 35 Previous studies have highlighted changes in resting membrane potential, spontaneous neuronal firing rates, synaptic strength, cerebral blood flow, and metabolism subsequent to tDCS.
14 Some authors have postulated an NMDA, 36 calcium uptake, 37 or dopaminergic modulation. 38 It should be noted that in the present study, 2 included patients in MCS received amantadine; however, the treatment was started 6 months prior to inclusion and remained unchanged during the experiment. We showed that tDCS in patients with DOC (when performed within established ranges of intensity and duration) is safe, and thus, could be tested as an alternative neuromodulatory tool to improve consciousness and cognitive function in severely brain-injured patients. Another form of noninvasive cortical stimulation is repetitive transcranial magnetic stimulation (rTMS). rTMS has previously been proposed in a single case study as a potential therapy for traumatic brain injury. 39 In our view, tDCS may have some advantages over rTMS, as it is easier to apply, causes less discomfort, and has a lower associated risk of inducing seizures 40 -the latter being especially important in the setting of severe brain injury.
Short-duration anodal (i.e., excitatory) tDCS of left DLPF cortex can induce short-term improvement in patients in MCS of acute/subacute and chronic etiologies measured by behavioral CRS-R total scores. The long-term noninvasive neuromodulatory tDCS outcome clinical improvement in this challenging patient population remains to be shown. Table 2 Treatment effects (i.e., change in CRS-R total score) for patients in VS/UWS and MCS Oral reflexive movement 0
Communication

Functional communication 2
Intentional communication 0
Arousal
Without stimulation 2
With stimulation 0
Abbreviations: CRS-R 5 Coma Recovery Scale-Revised; tDCS 5 transcranial direct current stimulation.
